Cabergoline for suppression of puerperal lactation in a prevention of mother-to-child HIV-transmission programme in rural Malawi.
AffiliationMedecins sans Frontieres, Thyolo District, Malawi.
MetadataShow full item record
AbstractThis study shows that cabergoline (single oral-dose) is an acceptable, safe and effective drug for suppressing puerperal lactation. It could be of operational benefit not only for artificial feeding, but also for weaning in those that breast-feed within preventive mother-to-child HIV transmission programmes in resource-limited settings.
PublisherRoyal Society of Medicine
- Prevention of puerperal lactation by a single oral administration of the new prolactin-inhibiting drug, cabergoline.
- Authors: Melis GB, Mais V, Paoletti AM, Beneventi F, Gambacciani M, Fioretti P
- Issue date: 1988 Mar
- Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
- Authors: Rains CP, Bryson HM, Fitton A
- Issue date: 1995 Feb
- Oral cabergoline. Single-dose inhibition of puerperal lactation.
- Authors: Caballero-Gordo A, Lopez-Nazareno N, Calderay M, Caballero JL, Mancheño E, Sghedoni D
- Issue date: 1991 Oct
- The combined oral contraceptive pill versus bromocriptine to suppress lactation in puerperium: a randomized double blind study.
- Authors: Piya-Anant M, Worapitaksanond S, Sittichai K, Saechua P, Nomrak A
- Issue date: 2004 Jun
- Cabergoline: a new drug for the treatment of hyperprolactinaemia.
- Authors: Ferrari C, Piscitelli G, Crosignani PG
- Issue date: 1995 Jul